DRMA
Dermata Therapeutics, Inc. NASDAQ Listed Aug 13, 2021$1.13
-0.95%
vs $1.14
Mkt Cap $769.6K
52w Low $0.95
3.6% of range
52w High $5.87
50d MA $1.27
200d MA $1.48
P/E (TTM)
—
EV/EBITDA
—
P/B
0.0x
Debt/Equity
0.0x
ROE
-121.4%
P/FCF
-0.0x
RSI (14)
38.70
ATR (14)
$0.08
Beta
0.50
50d MA
$1.27
200d MA
$1.48
Avg Volume
87.1K
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
CIK (SEC)
Phone
858 800 2543
3525 Del Mar Heights Road · San Diego, CA 92130 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | AMC | -0.55 | -0.74 | -34.5% | 1.08 | +16.7% | +27.8% | +13.8% | -7.0% | +0.0% | -2.1% | — |
| May 13, 2026 | AMC | -0.53 | -0.48 | +9.4% | 1.19 | +1.7% | +3.4% | -3.3% | +0.8% | -1.7% | +5.9% | — |
| Mar 26, 2026 | AMC | -1.54 | -1.52 | +1.3% | 1.37 | -0.7% | -13.9% | -3.4% | +6.1% | -0.8% | +7.5% | — |
| Nov 14, 2025 | AMC | -1.59 | -1.65 | -3.8% | 3.07 | +2.0% | -7.5% | -6.0% | -8.6% | +2.5% | +4.0% | — |
| Aug 13, 2025 | AMC | -2.90 | -1.66 | +42.8% | 6.45 | -1.4% | -9.9% | +2.9% | -1.0% | -4.7% | -4.1% | — |
| May 14, 2025 | AMC | -4.50 | -4.50 | +0.0% | 0.78 | -2.4% | +1.9% | -0.4% | +4.9% | -2.7% | -4.7% | — |
| Mar 17, 2025 | AMC | -15.00 | -13.40 | +10.7% | 1.17 | +0.0% | +2.6% | +1.7% | -3.3% | +5.1% | +4.8% | — |
| Nov 13, 2024 | AMC | -26.40 | -20.40 | +22.7% | 1.23 | +0.0% | -3.3% | -5.9% | -3.6% | +0.0% | +7.4% | — |
| Aug 7, 2024 | AMC | -37.90 | -41.80 | -10.3% | 2.33 | -7.7% | +12.4% | -6.1% | -7.7% | -2.6% | +2.3% | — |
| May 16, 2024 | AMC | -54.00 | -7.05 | +86.9% | 52.00 | -5.0% | -19.2% | -10.5% | -9.0% | +5.8% | -3.9% | — |
| May 15, 2024 | AMC | -5.40 | -7.05 | -30.6% | 4.95 | -2.0% | +5.1% | -19.2% | -10.5% | -9.0% | +5.8% | — |
| Mar 22, 2024 | AMC | -0.78 | -0.21 | +73.1% | 62.30 | +0.5% | +0.0% | -2.7% | -2.6% | +4.4% | +1.6% | — |
| Mar 21, 2024 | AMC | -0.78 | -3.15 | -303.8% | 6.00 | +8.8% | +3.8% | +0.0% | -2.7% | -2.6% | +4.4% | — |
| Nov 10, 2023 | AMC | -94.50 | -80.96 | +14.3% | 108.20 | -0.2% | -7.1% | -4.1% | +1.5% | +6.7% | +0.6% | — |
| Nov 9, 2023 | AMC | -0.63 | -8.10 | -1185.7% | 11.73 | -4.9% | -7.8% | -7.1% | -4.1% | +1.5% | +6.7% | — |
| Aug 10, 2023 | AMC | -0.92 | -9.45 | -927.2% | 17.40 | -0.9% | -2.6% | +2.7% | +1.7% | +6.8% | -3.2% | — |
| May 11, 2023 | AMC | -2.65 | -34.03 | -1184.2% | 28.95 | +71.0% | +35.2% | -1.1% | +0.8% | +3.5% | -8.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 21 | Maxim Group | Maintains | Buy → Buy | — | $5.41 | $5.24 | -3.1% | -1.5% | +2.8% | +6.4% | -5.7% | -3.8% |
| May 21 | Maxim Group | Maintains | Buy → Buy | — | $0.81 | $0.82 | +1.5% | -4.7% | -0.3% | -3.1% | +0.8% | -2.7% |
| Aug 21 | Maxim Group | Maintains | Buy → Buy | — | $2.02 | $2.03 | +0.5% | -4.0% | -5.2% | -2.7% | -5.6% | +3.6% |
| Mar 23 | Maxim Group | Maintains | Buy → Buy | — | $20.10 | $20.85 | +3.7% | +25.4% | -8.3% | -9.7% | -10.1% | +8.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Scott Kathleen D.Dir | — | Sell | 11 | $1.19 | $13 | — | +11.76% | -1.63% |
8-K · 1.01
! Medium
Dermata Therapeutics, Inc. -- 8-K 1.01: Equity Issuance
Dermata Therapeutics raised capital through a registered direct offering at $1.46 per share with warrants, providing investors equity upside at matching $1.46 exercise prices.
Aug 17
8-K · 2.02
!! High
Dermata Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Aug 11
8-K · 8.01
!! High
Dermata Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Aug 5
8-K · 5.02
!!! Very High
Dermata Therapeutics, Inc. -- 8-K 5.02: Executive Change
May 27
8-K
Unknown — 8-K Filing
Dermata reported 2025 year-end results via 8-K filing, signaling material corporate developments that investors should monitor for revenue trends, profitability changes, and strategic direction affecting stock valuation.
Mar 26
8-K · 5.02
!!! Very High
Dermata Therapeutics, Inc. -- 8-K 5.02: Executive Change
Dermata Therapeutics loses director Mary Fisher on March 31, 2026, representing a board-level departure that investors should monitor for potential strategic implications.
Feb 25
8-K · 4.01
!!! Very High
Dermata Therapeutics, Inc. -- 8-K 4.01: Auditor Change / Resignation
Dermata Therapeutics dismissed its independent auditor, a routine corporate housekeeping change that typically signals either cost management or dissatisfaction with audit quality and services.
Feb 3
Institutional (13F) — Top 6
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Ubs Group Ag | 35,608 | $43K | Added | Mar 2026 |
| 2 | Welch & Forbes Llc | 20,000 | $24K | New | Mar 2026 |
| 3 | Advisory Alpha, Llc | 10,000 | $13K | New | Jun 2026 |
| 4 | Mcf Advisors Llc | 1,732 | $2K | New | Mar 2026 |
| 5 | Sbi Securities Co., Ltd. | 101 | $130 | New | Jun 2026 |
| 6 | Highline Wealth Partners Llc | 26 | $34 | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 6
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Equity ETF | 843,000 | $54K | Feb 2026 |
| 2 | Avantis Emerging Markets Value ETF | 468,500 | $30K | Feb 2026 |
| 3 | Fidelity Extended Market Index Fund | 21,540 | $26K | Feb 2026 |
| 4 | Avantis Emerging Markets Equity Fund | 280,300 | $18K | Feb 2026 |
| 5 | Avantis Responsible Emerging Markets Equity ETF | 126,400 | $8K | Feb 2026 |
| 6 | Fidelity Series Total Market Index Fund | 1,106 | $1K | May 2026 |
Valuation
Market Cap
$770K
Enterprise Value
-$7.52B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.00x
P/B
0.00x
P/S
—
P/FCF
-0.00x
EV/EBITDA
—
Shares Out
926K
Financials (TTM)
Revenue
$0
Net Income
-$8.4M
EBITDA
-$8.5M
Free Cash Flow
-$7.76B
Op Cash Flow
-$7.76B
EPS Basic
$-8.16
EPS Diluted
$-4.39
EPS Forward
$-2.20
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$7.86B
Total Liab.
$1.64B
Total Equity
$6.22B
Cash
$7.52B
LT Debt
$0
Book Value/Sh
$6719.32
Debt/Equity
0.00x
Current Ratio
4585.32
Quick Ratio
4585.32
Returns & Growth
ROE
-121.4%
ROA
-96.1%
ROIC
-0.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
+89.8%
Price Returns
2W
-4.2%
1M
-29.2%
3M
-11.6%
6M
-16.8%
12M
-78.0%
Technicals
52W High
$5.87
52W Low
$0.95
50d MA
$1.27
200d MA
$1.48
RSI (14)
38.70
ATR (14)
$0.08
Beta
0.50
Avg Volume
87K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$6.00
Low
$6.00
Median
$6.00
Data updated apr 25, 2026 5:46am
· Source: financialmodelingprep.com